We want to thank those of you who have continued to subscribe to our blog and who have visited our website. Some have written noting particular interest in the research conducted at the MGH Center for Women’s Mental Health, including the National Pregnancy Registry for Atypical Antipsychotics.

The purpose of the National Pregnancy Registry for Atypical Antipsychotics (NPRAA) is to determine the safety of fetal exposure to atypical antipsychotics.  Medications in this class include Abilify (Ariprazole), Seroquel (Quetiapine), Zyprexa (Olanzapine), Geodon (Ziprasidone), Risperidone (Risperdal), Saphris (Asenapine), Clozaril (Clozapine), Fanapt (Iloperidone), Latuda (Lurasidone), and Paliperidone (Invega).

We are studying rates of malformations following fetal exposure to atypical antipsychotics, as well as other maternal and newborn outcomes including rates of obstetrical complications, birth weight, and weight gain across pregnancy. We systematically gather data from women who are taking an atypical antipsychotic during pregnancy and a comparison group of women without in utero exposure to this class of medicine.

Participation in the Registry involves 3 brief phone interviews over a period of approximately 8 months.  We also request copies of the medical records of both mother and child as part of study participation. More information can be found at www.womensmentalhealth.org/pregnancyregistry .

We appreciate the effort of clinicians who have referred patients to participate in the Registry. We also wish to thank the many patients who read our blog who have participated in the National Pregnancy Registry for Atypical Antipsychotics.

The Registry is a patient-initiated study — if you are interested in referring someone to the Registry, please have the woman call 1-866-961-2388 or email us at registry@womensmentalhealth.org.  If you have other questions about the Registry, please also feel free to contact us.

 

Lee S. Cohen, MD

Adele Viguera, MD, MPH